BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 12489026)

  • 1. Replicative retroviral vectors for cancer gene therapy.
    Solly SK; Trajcevski S; Frisén C; Holzer GW; Nelson E; Clerc B; Abordo-Adesida E; Castro M; Lowenstein P; Klatzmann D
    Cancer Gene Ther; 2003 Jan; 10(1):30-9. PubMed ID: 12489026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
    Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
    Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors.
    Indraccolo S; Habeler W; Tisato V; Stievano L; Piovan E; Tosello V; Esposito G; Wagner R; Uberla K; Chieco-Bianchi L; Amadori A
    Cancer Res; 2002 Nov; 62(21):6099-107. PubMed ID: 12414634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
    Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
    J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a semi-replicative gene delivery system allowing propagation of complementary defective retroviral vectors.
    Trajcevski S; Solly SK; Frisén C; Trenado A; Cosset FL; Klatzmann D
    J Gene Med; 2005 Mar; 7(3):276-87. PubMed ID: 15515136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgene inheritance and retroviral infection contribute to the efficiency of gene expression in solid tumors inoculated with retroviral vector producer cells.
    Tamiya T; Wei MX; Chase M; Ono Y; Lee F; Breakefield XO; Chiocca EA
    Gene Ther; 1995 Oct; 2(8):531-8. PubMed ID: 8593603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector.
    Feng M; Jackson WH; Goldman CK; Rancourt C; Wang M; Dusing SK; Siegal G; Curiel DT
    Nat Biotechnol; 1997 Sep; 15(9):866-70. PubMed ID: 9306401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
    Akbulut H; Zhang L; Tang Y; Deisseroth A
    Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TK-GFP fusion gene virus vectors as tools for studying the features of HSV-TK/ganciclovir cancer gene therapy in vivo.
    Pasanen T; Hakkarainen T; Timonen P; Parkkinen J; Tenhunen A; Loimas S; Wahlfors J
    Int J Mol Med; 2003 Oct; 12(4):525-31. PubMed ID: 12964030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.
    Kikuchi E; Menendez S; Ozu C; Ohori M; Cordon-Cardo C; Logg CR; Kasahara N; Bochner BH
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4511-8. PubMed ID: 17671137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
    Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
    Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgene amplification and persistence after delivery of retroviral vector and packaging functions with E1/E4-deleted adenoviruses.
    Torrent C; Jullien C; Klatzmann D; Perricaudet M; Yeh P
    Cancer Gene Ther; 2000 Aug; 7(8):1135-44. PubMed ID: 10975674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors.
    Tai KF; Chen PJ; Chen DS; Hwang LH
    J Gene Med; 2003 May; 5(5):386-98. PubMed ID: 12731087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
    Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.
    McCart JA; Ward JM; Lee J; Hu Y; Alexander HR; Libutti SK; Moss B; Bartlett DL
    Cancer Res; 2001 Dec; 61(24):8751-7. PubMed ID: 11751395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication.
    Huarte E; Larrea E; Hernández-Alcoceba R; Alfaro C; Murillo O; Arina A; Tirapu I; Azpilicueta A; Hervás-Stubbs S; Bortolanza S; Pérez-Gracia JL; Civeira MP; Prieto J; Riezu-Boj JI; Melero I
    Mol Ther; 2006 Jul; 14(1):129-38. PubMed ID: 16627004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell-specific expression from Mo-MLV retroviral vectors containing a CD4 mini-promoter/enhancer.
    Zhao-Emonet JC; Marodon G; Pioche-Durieu C; Cosset FL; Klatzmann D
    J Gene Med; 2000; 2(6):416-25. PubMed ID: 11199262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy.
    Crittenden M; Gough M; Chester J; Kottke T; Thompson J; Ruchatz A; Clackson T; Cosset FL; Chong H; Diaz RM; Harrington K; Alvarez Vallina L; Vile R
    Cancer Res; 2003 Jun; 63(12):3173-80. PubMed ID: 12810645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct.
    Hakkarainen T; Wahlfors T; Meriläinen O; Loimas S; Hemminki A; Wahlfors J
    J Gene Med; 2005 Jul; 7(7):898-907. PubMed ID: 15759279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor effect of recombinant retroviral vector-mediated human ANGPTL4 gene transfection.
    Li KQ; Li WL; Peng SY; Shi XY; Tang HL; Liu YB
    Chin Med J (Engl); 2004 Sep; 117(9):1364-9. PubMed ID: 15377430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.